Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease

The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally considered causal for synaptic loss and neurodegeneration in AD. We elaborate on and update arguments for and against t...

Full description

Saved in:
Bibliographic Details
Published in:Acta neuropathologica communications 2014-09, Vol.2 (1), p.135, Article 135
Main Authors: Morris, Gary P, Clark, Ian A, Vissel, Bryce
Format: Article
Language:English
Subjects:
Advertising executives
Alzheimer Disease - etiology
Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Amyloid beta-Peptides - metabolism
Amyloid beta-protein
Development and progression
Disease susceptibility
Genetic aspects
Humans
Neurofibrillary Tangles - pathology
Plaque, Amyloid - pathology
Review
Synapses - pathology
tau Proteins - adverse effects
tau Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3
cites cdi_FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3
container_end_page
container_issue 1
container_start_page 135
container_title Acta neuropathologica communications
container_volume 2
creator Morris, Gary P
Clark, Ian A
Vissel, Bryce
description The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally considered causal for synaptic loss and neurodegeneration in AD. We elaborate on and update arguments for and against the amyloid hypothesis with new data and interpretations, and consider why the amyloid hypothesis may be failing therapeutically. We note several unresolved issues in the field including the presence of Aβ deposition in cognitively normal individuals, the weak correlation between plaque load and cognition, questions regarding the biochemical nature, presence and role of Aβ oligomeric assemblies in vivo, the bias of pre-clinical AD models toward the amyloid hypothesis and the poorly explained pathological heterogeneity and comorbidities associated with AD. We also illustrate how extensive data cited in support of the amyloid hypothesis, including genetic links to disease, can be interpreted independently of a role for Aβ in AD. We conclude it is essential to expand our view of pathogenesis beyond Aβ and tau pathology and suggest several future directions for AD research, which we argue will be critical to understanding AD pathogenesis.
doi_str_mv 10.1186/s40478-014-0135-5
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4207354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541269890</galeid><sourcerecordid>A541269890</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3</originalsourceid><addsrcrecordid>eNptUV1LwzAUDaK4MfcDfJGCoE-d-Wja5EUYw4_BwBd98iGk7e0aaZuRdIP5682Yjg1MCElOzjnc3IPQNcETQkT64BOcZCLGJAmL8ZifoSHFnMRcpvj86DxAY--_cBiSECbEJRpQThnBqRiiz3lX2M4b30NXGPCR7sooIL2zG3B-h_i1c3bdlaZbRn0NkW63jTVlVG9XNtyDNrJVNG2-azAtuHsflcaD9nCFLirdeBj_7iP08fz0PnuNF28v89l0EReJzPqYMc05z4FwwHmBgWVcYykFpSVLJBNZxQSjFOcZyyXQXAYCKwmFnKVcZjkboce972qdt1AWEKrXjVo502q3VVYbdfrSmVot7UYlFGeMJ8Hgdm-w1A0o01U20IrW-EJNeUJoKoXEgTX5hxVmCa0JLYPKBPxEcHckqEE3fe1ts-5N6PgpkeyJhbPeO6gOtROsdmGrfdgqhK12YSseNDfHnz4o_qJlPzovpLE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease</title><source>PubMed Central</source><creator>Morris, Gary P ; Clark, Ian A ; Vissel, Bryce</creator><creatorcontrib>Morris, Gary P ; Clark, Ian A ; Vissel, Bryce</creatorcontrib><description>The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally considered causal for synaptic loss and neurodegeneration in AD. We elaborate on and update arguments for and against the amyloid hypothesis with new data and interpretations, and consider why the amyloid hypothesis may be failing therapeutically. We note several unresolved issues in the field including the presence of Aβ deposition in cognitively normal individuals, the weak correlation between plaque load and cognition, questions regarding the biochemical nature, presence and role of Aβ oligomeric assemblies in vivo, the bias of pre-clinical AD models toward the amyloid hypothesis and the poorly explained pathological heterogeneity and comorbidities associated with AD. We also illustrate how extensive data cited in support of the amyloid hypothesis, including genetic links to disease, can be interpreted independently of a role for Aβ in AD. We conclude it is essential to expand our view of pathogenesis beyond Aβ and tau pathology and suggest several future directions for AD research, which we argue will be critical to understanding AD pathogenesis.</description><identifier>ISSN: 2051-5960</identifier><identifier>EISSN: 2051-5960</identifier><identifier>DOI: 10.1186/s40478-014-0135-5</identifier><identifier>PMID: 25231068</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Advertising executives ; Alzheimer Disease - etiology ; Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Amyloid beta-Peptides - metabolism ; Amyloid beta-protein ; Development and progression ; Disease susceptibility ; Genetic aspects ; Humans ; Neurofibrillary Tangles - pathology ; Plaque, Amyloid - pathology ; Review ; Synapses - pathology ; tau Proteins - adverse effects ; tau Proteins - metabolism</subject><ispartof>Acta neuropathologica communications, 2014-09, Vol.2 (1), p.135, Article 135</ispartof><rights>COPYRIGHT 2014 BioMed Central Ltd.</rights><rights>Morris et al.; licensee BioMed Central Ltd. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3</citedby><cites>FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207354/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207354/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25231068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morris, Gary P</creatorcontrib><creatorcontrib>Clark, Ian A</creatorcontrib><creatorcontrib>Vissel, Bryce</creatorcontrib><title>Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease</title><title>Acta neuropathologica communications</title><addtitle>Acta Neuropathol Commun</addtitle><description>The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally considered causal for synaptic loss and neurodegeneration in AD. We elaborate on and update arguments for and against the amyloid hypothesis with new data and interpretations, and consider why the amyloid hypothesis may be failing therapeutically. We note several unresolved issues in the field including the presence of Aβ deposition in cognitively normal individuals, the weak correlation between plaque load and cognition, questions regarding the biochemical nature, presence and role of Aβ oligomeric assemblies in vivo, the bias of pre-clinical AD models toward the amyloid hypothesis and the poorly explained pathological heterogeneity and comorbidities associated with AD. We also illustrate how extensive data cited in support of the amyloid hypothesis, including genetic links to disease, can be interpreted independently of a role for Aβ in AD. We conclude it is essential to expand our view of pathogenesis beyond Aβ and tau pathology and suggest several future directions for AD research, which we argue will be critical to understanding AD pathogenesis.</description><subject>Advertising executives</subject><subject>Alzheimer Disease - etiology</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Amyloid beta-protein</subject><subject>Development and progression</subject><subject>Disease susceptibility</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Neurofibrillary Tangles - pathology</subject><subject>Plaque, Amyloid - pathology</subject><subject>Review</subject><subject>Synapses - pathology</subject><subject>tau Proteins - adverse effects</subject><subject>tau Proteins - metabolism</subject><issn>2051-5960</issn><issn>2051-5960</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNptUV1LwzAUDaK4MfcDfJGCoE-d-Wja5EUYw4_BwBd98iGk7e0aaZuRdIP5682Yjg1MCElOzjnc3IPQNcETQkT64BOcZCLGJAmL8ZifoSHFnMRcpvj86DxAY--_cBiSECbEJRpQThnBqRiiz3lX2M4b30NXGPCR7sooIL2zG3B-h_i1c3bdlaZbRn0NkW63jTVlVG9XNtyDNrJVNG2-azAtuHsflcaD9nCFLirdeBj_7iP08fz0PnuNF28v89l0EReJzPqYMc05z4FwwHmBgWVcYykFpSVLJBNZxQSjFOcZyyXQXAYCKwmFnKVcZjkboce972qdt1AWEKrXjVo502q3VVYbdfrSmVot7UYlFGeMJ8Hgdm-w1A0o01U20IrW-EJNeUJoKoXEgTX5hxVmCa0JLYPKBPxEcHckqEE3fe1ts-5N6PgpkeyJhbPeO6gOtROsdmGrfdgqhK12YSseNDfHnz4o_qJlPzovpLE</recordid><startdate>20140918</startdate><enddate>20140918</enddate><creator>Morris, Gary P</creator><creator>Clark, Ian A</creator><creator>Vissel, Bryce</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140918</creationdate><title>Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease</title><author>Morris, Gary P ; Clark, Ian A ; Vissel, Bryce</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Advertising executives</topic><topic>Alzheimer Disease - etiology</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Amyloid beta-protein</topic><topic>Development and progression</topic><topic>Disease susceptibility</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Neurofibrillary Tangles - pathology</topic><topic>Plaque, Amyloid - pathology</topic><topic>Review</topic><topic>Synapses - pathology</topic><topic>tau Proteins - adverse effects</topic><topic>tau Proteins - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morris, Gary P</creatorcontrib><creatorcontrib>Clark, Ian A</creatorcontrib><creatorcontrib>Vissel, Bryce</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Acta neuropathologica communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morris, Gary P</au><au>Clark, Ian A</au><au>Vissel, Bryce</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease</atitle><jtitle>Acta neuropathologica communications</jtitle><addtitle>Acta Neuropathol Commun</addtitle><date>2014-09-18</date><risdate>2014</risdate><volume>2</volume><issue>1</issue><spage>135</spage><pages>135-</pages><artnum>135</artnum><issn>2051-5960</issn><eissn>2051-5960</eissn><abstract>The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years. We review why accumulation of amyloid-beta (Aβ) oligomers is generally considered causal for synaptic loss and neurodegeneration in AD. We elaborate on and update arguments for and against the amyloid hypothesis with new data and interpretations, and consider why the amyloid hypothesis may be failing therapeutically. We note several unresolved issues in the field including the presence of Aβ deposition in cognitively normal individuals, the weak correlation between plaque load and cognition, questions regarding the biochemical nature, presence and role of Aβ oligomeric assemblies in vivo, the bias of pre-clinical AD models toward the amyloid hypothesis and the poorly explained pathological heterogeneity and comorbidities associated with AD. We also illustrate how extensive data cited in support of the amyloid hypothesis, including genetic links to disease, can be interpreted independently of a role for Aβ in AD. We conclude it is essential to expand our view of pathogenesis beyond Aβ and tau pathology and suggest several future directions for AD research, which we argue will be critical to understanding AD pathogenesis.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>25231068</pmid><doi>10.1186/s40478-014-0135-5</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2051-5960
ispartof Acta neuropathologica communications, 2014-09, Vol.2 (1), p.135, Article 135
issn 2051-5960
2051-5960
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4207354
source PubMed Central
subjects Advertising executives
Alzheimer Disease - etiology
Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Amyloid beta-Peptides - metabolism
Amyloid beta-protein
Development and progression
Disease susceptibility
Genetic aspects
Humans
Neurofibrillary Tangles - pathology
Plaque, Amyloid - pathology
Review
Synapses - pathology
tau Proteins - adverse effects
tau Proteins - metabolism
title Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T17%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inconsistencies%20and%20controversies%20surrounding%20the%20amyloid%20hypothesis%20of%20Alzheimer's%20disease&rft.jtitle=Acta%20neuropathologica%20communications&rft.au=Morris,%20Gary%20P&rft.date=2014-09-18&rft.volume=2&rft.issue=1&rft.spage=135&rft.pages=135-&rft.artnum=135&rft.issn=2051-5960&rft.eissn=2051-5960&rft_id=info:doi/10.1186/s40478-014-0135-5&rft_dat=%3Cgale_pubme%3EA541269890%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c497t-33a555be15e0bc0e375a099822d349387f383220b73b9e2b93753d12eb36597b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/25231068&rft_galeid=A541269890&rfr_iscdi=true